The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Joint AASLD/IDSA practice recommendations reflect new data on prevention, treatment, and surveillance of chronic hepatitis B, ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms ...

A peer navigator intervention following a nonfatal opioid overdose in the emergency department does not significantly reduce ...

Walk-in appointments can reduce the time to pediatric dermatology visits for both atopic dermatitis and hidradenitis suppurativa and reduce ED visits for atopic dermatitis, a study finds.

Thirty years after its discovery, scientists are eyeing leptin with renewed interest, for everything from weight loss drug ...

Cardiovascular mortality among US adults with obesity tripled from 1999 to 2023, with persistent and widening disparities across certain sociodemographic and geographic groups.

Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

A new consensus statement from the American Society of Clinical Psychopharmacology offers guidance on when — and whether — to discontinue psychotropic medications.

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.